

AUTHOR INDEX FOR VOLUME 39

A

- Alberts, D. W., *see* Hoke, G. D., 90
 Allegra, C. J., *see* Chu, E., 136
 Aller, P., *see* Rius, C., 442
 Anundi, I., *see* Kauffman, F. C., 414
 Arneson-Rotert, L. J., *see* Johnson, R. A., 399
 Artymyshyn, R. P., *see* Ivins, K. J., 531
 Arvidsson, L.-E., *see* Cornfield, L. J., 780
 Audhya, T., *see* Quik, M., 324
 Audinat, E., *see* Geoffroy, M., 587
 August, E. M., Birks, E. M., and Prusoff, W. H. 3'-deoxythymidin-2'-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion, 246
 Axelrod, J., *see* Kanterman, R. Y., 364

B

- Baba, M., De Clercq, E., Tanaka, H., Ubasawa, M., Takashima, H., Sekiya, K., Nitta, I., Umezu, K., Walker, R. T., Mori, S., Ito, M., Shigeta, S., and Miyasaka, T. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclovir derivatives, 805
 Baird, J. G., Challiss, R. A. J., and Nahorski, S. R. Role for ionotropic and metabotropic receptors in quisqualate-stimulated inositol polyphosphate accumulation in rat cerebral cortex, 745
 Ballesteros, L. A., *see* Potter, L. T., 211
 Balzarini, J., *see* Cools, M., 718
 Barchi, R. L., *see* White, M. M., 604
 Barton, A. C., Black, L. E., and Sibley, D. R. Agonist-induced desensitization of D₂ dopamine receptors in human Y-79 retinoblastoma cells, 650
 Bartus, J. O., *see* Hoke, G. D., 90
 Bates, M. D., Senogles, S. E., Bunzow, J. R., Liggett, S. B., Civelli, O., and Caron, M. G. Regulation of responsiveness at D₂ dopamine receptors by receptor desensitization and adenylyl cyclase sensitization, 55
 Bauer, P. H., Chiu, A. T., and Garrison, J. C. DuP 753 can antagonize the effects of angiotensin II in rat liver, 579
 Beardsley, G. P., *see* Pizzorno, G., 85
 Beaufort, P., *see* Chatelain, P., 64
 Beddell, C. R., *see* Gartland, K. P. R., 629
 Beer, M., *see* Grant, D. M., 184
 Beerman, T. A., *see* Vertino, P. M., 487
 Bell, K., *see* Klijn, K., 407
 Berger, S. P., Martenson, R. E., Laing, P., Thurkauf, A., Decosta, B., Rice, K. C., and Paul, S. M. Photoaffinity labeling of the dopamine reuptake carrier protein with 3-azido[³H]GBR-12935, 429
 Bergeron, R. J., *see* Vertino, P. M., 487
 Bernabeu, C., *see* Rius, C., 442
 Bernad, N., *see* Lignon, M.-F., 615
 Bernstrom, K., Malcolm, K., McGee, J., MacIouf, J., Levy-Toledano, S., Falck, J. R., and Fitzpatrick, F. A. 14,15-cis-episulfide-eicosatrienoic acid, an "epoxygenase" eicosanoid analog, inhibits ionophore- but not thrombin-induced platelet aggregation, 114
 Bevan, R. J., *see* Cretton, E. M., 258
 Bianchi, B. R., *see* Lin, C. W., 346
 Bichajian, L. H., *see* Potter, L. T., 211
 Bielawska, A., *see* Werner, M. H., 547
 Birks, E. M., *see* August, E. M., 246
 Birnbaum, L. S., *see* Lin, F. H., 307
 Black, L. E., *see* Barton, A. C., 650
 Blakeman, D. P., *see* Im, W. B., 394
 Blank, J. A., *see* Clark, G. C., 495

- Blum, M., *see* Grant, D. M., 184
 Boja, J. W., Rahman, M. A., Philip, A., Lewin, A. H., Carroll, F. I., and Kuhar, M. J. Isothiocyanate derivatives of cocaine: Irreversible inhibition of ligand binding at the dopamine transporter, 339
 Boksa, P., *see* Mount, H., 205
 Bovolin, P., *see* Memo, M., 599
 Bradfield, C. A., Glover, E., and Poland, A. Purification and N-terminal amino acid sequence of the Ah receptor from the C57BL/6J mouse, 13
 Bradfield, C. A., *see* Poland, A., 20
 Brandon, S., *see* Wilson, A. L., 481
 Brennscheidt, U., *see* Henschler, R., 171
 Briley, E. M., *see* Kanterman, R. Y., 364
 Brooks, B. P., *see* Ferris, C. D., 199
 Brune, B., and Ullrich, V. 12-Hydroperoxyeicosatetraenoic acid inhibits main platelet functions by activation of soluble guanylate cyclase, 671
 Brune, K. A., *see* Saussy, D. L., Jr., 72
 Bunzow, J. R., *see* Bates, M. D., 55
 Burchell, B., *see* Fournel-Gigleux, S., 177
 Bûrgin, M., *see* Huwyler, J., 314
 Burman, M., *see* Torphy, T. J., 376
 Bylund, D. B., *see* Jones, S. B., 239

C

- Cabañas, C., *see* Rius, C., 442
 Caffrey, P. B. and Frenkel, G. D. Inhibition of cell colony formation by selenite: Involvement of glutathione, 281
 Campbell, P. T., Hnatowich, M., O'Dowd, B. F., Caron, M. G., Lefkowitz, R. J., and Hausdorff, W. P. Mutations of the human β_2 -adrenergic receptor that impair coupling to G_i interfere with receptor down-regulation but not sequestration, 192
 Caron, M. G., *see* Bates, M. D., 55
 Caron, M. G., *see* Campbell, P. T., 192
 Carroll, F. I., *see* Boja, J. W., 339
 Cashmore, A. R., *see* Pizzorno, G., 85
 Castle, N. A., *see* Nettleton, J., 352
 Catt, K. J., *see* Ji, H., 120
 Catt, K. J., *see* Stojilković, S. S., 762
 Challiss, R. A. J., *see* Baird, J. G., 745
 Chatelain, P., Beaufort, P., Meysmans, L., and Clinet, M. Characterization of the slow calcium channel binding sites for [³H]SR 33557 in rat heart sarcolemmal membranes, 64
 Chatterjee, T. K., and Fisher, R. A. Multiple affinity forms of the calcitonin gene-related peptide receptor in rat cerebellum, 798
 Chaudieu, I., *see* Mount, H., 205
 Chen, C.-H., Vazquez-Padua, M., and Cheng, Y.-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity, 625
 Chen, L., *see* White, M. M., 604
 Cheng, Y.-C., *see* Chen, C.-H., 625
 Cheng, Y.-C., *see* Lewandowski, G. A., 27
 Chew, C., Villar, H. O., and Loew, G. H. Theoretical study of the flexibility and solution conformation of the cyclic opioid peptides [D-Pen²,D-Pen⁵]enkephalin and [D-Pen²,L-Pen⁵]enkephalin, 502
 Chiu, A. T., *see* Bauer, P. H., 579
 Chou, T.-C., *see* Kong, X.-B., 250
 Chu, E., Drake, J. C., Koeller, D. M., Zinn, S., Jamis-Dow, C. A., Yeh, G. C., and Allegra, C. J. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines, 136
 Cieslinski, L. B., *see* McHale, M. M., 109

- Civelli, O., *see* Bates, M. D., 55
 Clark, G., *see* Lin, F. H., 307
 Clark, G. C., Blank, J. A., Germolec, D. R., and Luster, M. I. 2,3,7,8-tetrachlorodibenzo-*p*-dioxin stimulation of tyrosine phosphorylation in B lymphocytes: Potential role in immunosuppression, 495
 Clark, R. B., *see* Proll, M. A., 740
 Clinet, M., *see* Chatelain, P., 64
 Cohn, J. A., *see* Schwartz, R. D., 370
 Cooke, A. M., *see* Safrany, S. T., 754
 Cools, M., Balzarini, J., and De Clercq, E. Mechanism of antiviral and cytotoxic action of ($\pm$)-6' β -fluoroaristeromycin, a potent inhibitor of *S*-adenosylhomocysteine hydrolase, 718
 Corcoran, G. B., *see* Raucy, J. L., 275
 Cornfield, L. J., Lambert, G., Arvidsson, L.-E., Mellin, C., Vallgård, J., Hacksell, U., and Nelson, D. L. Intrinsic activity of enantiomers of 8-hydroxy-2-(di-*n*-propylamino)tetralin and its analogs at 5-hydroxytryptamine_{1A} receptors that are negatively coupled to adenylate cyclase, 780
 Costa, E., *see* Fabrazzo, M., 144
 Costa, E., *see* Memo, M., 599
 Costa, E., *see* Puia, G., 691
 Covey, D. F., *see* Holland, K. D., 79
 Cragoe, E. J., Jr., *see* Wilson, A. L., 481
 Craig, R., *see* Lin, C. W., 346
 Crepel, F., *see* Geoffroy, M., 587
 Cretton, E. M., Xie, M.-Y., Bevan, R. J., Goudgaon, N. M., Schinazi, R. F., and Sommadossi, J. P. Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells, 258
 Cross, A. D., *see* Pizzorno, R., 85
 Culig, H., *see* Krug, H. F., 511
- D**
- Davis, M. A., *see* Dusenbury, C. E., 285
 De Clercq, E., *see* Baba, M., 805
 De Clercq, E., *see* Cools, M., 718
 De Clercq, E., *see* Jansen, R. W., 818
 Decosta, B., *see* Berger, S. P., 429
 De Costa, B. R., *see* Rothman, R. B., 222
 Dhawan, S., *see* Pabreza, L. A., 9
 Diamond, J., *see* Hei, Y. J., 233
 Dinarello, C. A., *see* Miller, L. G., 105
 Di Paolo, T., *see* Lévesque, D., 659
 Do, U. H., *see* Jarvis, M. F., 49
 Dong, Z., Ward, N. E., Fan, D., Gupta, K. P., and O'Brian, C. A. *In vitro* model for intrinsic drug resistance: Effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells, 563
 Drake, J. C., *see* Chu, E., 136
 Dubé, G. P., *see* Saussy, D. L., Jr., 72
 Duniec, Z. M., Nettesheim, P., and Eling, T. E. Stimulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by phorbol ester: Mediation by protein kinase C, 164
 Dunlap, K., *see* Miller, L. G., 105
 Dusenbury, C. E., Davis, M. A., Lawrence, T. S., and Maybaum, J. Induction of megabase DNA fragments by 5-fluorodeoxyuridine in human colorectal tumor (HT29) cells, 285
- E**
- Edgar, P. P., *see* Schwartz, R. D., 370
 El-Bizri, H., *see* Quik, M., 324
 Eling, T. E., *see* Duniec, Z. M., 164
 Eng, W.-K., *see* McHale, M. M., 109
- F**
- Fabrazzo, M., Costa, E., and Mochetti, I. Stimulation of nerve growth factor biosynthesis in developing rat brain by reserpine: Steroids as potential mediators, 144
 Fahl, W. E., *see* Manoharan, T. H., 461
 Falck, J. R., *see* Bernstrom, K., 114
 Fan, D., *see* Dong, Z., 563
 Faucette, L. F., *see* Hoke, G. D., 90
 Felder, C. C., *see* Kanterman, R. Y., 364
 Ferrendelli, C. A., *see* Potter, L. T., 211
 Ferrendelli, J. A., *see* Holland, K. D., 79
 Ferris, C. D., Hirsch, D. J., Brooks, B. P., Snowman, A. M., and Snyder, S. H. [³H]Opipramol labels a novel binding site and σ receptors in rat brain membranes, 199
 Fisher, A., *see* Potter, L. T., 211
 Fisher, R. A., *see* Chatterjee, T. K., 798
 Fitzpatrick, F. A., *see* Bernstrom, K., 114
 Flagg, S., *see* Wall, S. J., 643
 Ford, J., *see* Ganapathi, R., 1
 Forman, S. A., *see* Wood, S. C., 332
 Fournel-Gigleux, S., Sutherland, L., Sabolovic, N., Burchell, B., and Siest, G. Stable expression of two human UDP-glucuronosyltransferase cDNAs in V79 cell cultures, 177
 Frenkel, G. D., *see* Caffrey, P. B., 281
 Funae, Y., *see* Kanazawa, Y., 456
- G**
- Galpern, W. R., *see* Miller, L. G., 105
 Ganapathi, R., Kuo, T., Teeter, L., Grabowski, D., and Ford, J. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells, 1
 Garrison, J. C., *see* Bauer, P. H., 579
 Gartland, K. P. R., Beddell, C. R., Lindon, J. C., and Nicholson, J. K. Application of pattern recognition methods to the analysis and classification of toxicological data derived from proton nuclear magnetic resonance spectroscopy of urine, 629
 Geoffroy, M., Lambolez, B., Audinat, E., Hamon, B., Crepel, F., Rossier, J., and Kado, R. T. Reduction of desensitization of the α -amino-3-hydroxy-5-methylisoxazole-4-propionate receptor by 6-cyano-7-nitroquinoxaline-2,3-dione and 6,7-dinitroquinoxaline-2,3-dione, 587
 Germolec, D. R., *see* Clark, G. C., 495
 Ginns, E. I., *see* Montpied, P., 157
 Ginns, E. I., *see* Wall, S. J., 643
 Glover, E., *see* Bradfield, C. A., 13
 Glover, E., *see* Poland, A., 20
 Goldstein, G., *see* Quik, M., 324
 Goldstein, J. A., *see* Lin, F. H., 307
 Goudgaon, N. M., *see* Cretton, E. M., 258
 Grabowski, D., *see* Ganapathi, R., 1
 Grant, D. M., Blum, M., Beer, M., and Meyer, U. A. Monomorphic and polymorphic human arylamine *N*-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes, 184
 Grayson, D. R., *see* Memo, M., 599
 Gross, W. and Lohse, M. J. Mechanism of activation of A₂ adenosine receptors. II. A restricted collision-coupling model of receptor-effector interaction, 524
 Gulick, A. M., *see* Manoharan, T. H., 461
 Gunji, H., *see* Rubin, E., 697
 Gupta, K. P., *see* Dong, Z., 563
 Gusovsky, F. and Gutkind, J. S. Selective effects of activation of protein kinase C isozymes on cyclic AMP accumulation, 124
 Gut, J., *see* Huwyler, J., 314
 Guthrie, T. S., Tsuji, J.-I., and Wells, J. N. A synthetic pseudosubstrate peptide of protein kinase C inhibits the phorbol-12,13-dibutyrate effect on permeabilized coronary artery smooth muscle, 621
 Gutkind, J. S., *see* Gusovsky, F., 124

H

- Hacksell, U., *see* Cornfield, L. J., 780
Halenda, S. P., *see* Jones, S. B., 239
Hammond, J. R. Kinetic analysis of ligand binding to the Ehrlich cell nucleoside transporter: Pharmacological characterization of allosteric interaction with the [³H]nitrobenzylthioinosine binding site, 771
Hamon, B., *see* Geoffroy, M., 587
Hanchett, H. E., *see* Potter, L. T., 211
Hannun, Y. A., *see* Werner, M. H., 547
Hausdorff, W. P., *see* Campbell, P. T., 192
Hei, Y.-J., MacDonell, K. L., McNeill, J. H., and Diamond, J. Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs, 233
Henningsen, R. A., *see* Neve, K. A., 733
Henschler, R., Brennscheidt, U., Mertelsmann, R., and Herrmann, F. Induction of *c-jun* expression in the myeloid leukemia cell line KG-1 by 1- β -D-arabinofuranosylcytosine, 171
Herrmann, F., *see* Henschler, R., 171
Herschkowitz, N., and Rogawski, M. A. Tetrahydroaminoacridine block of *N*-methyl-D-aspartate-activated cation channels in cultured hippocampal neurons, 592
Heuschneider, G., *see* Schwartz, R. D., 370
Heys, J. R., *see* Hoke, G. D., 90
Hill, R. J., *see* Sheldon, R. S., 609
Hirsch, D. J., *see* Ferris, C. D., 199
Hnatowich, M., *see* Campbell, P. T., 192
Hoffman, J. M., *see* Johnson, R. A., 399
Hoke, G. D., McCabe, F. L., Faucette, L. F., Bartus, J. O., Sung, C. M., Jensen, B. C., Heys, J. R., Rush, G. F., Alberts, D. W., Johnson, R. K., and Mirabelli, C. K. *In vivo* development and *in vitro* characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane, 90
Holland, K. D., Yoon, K.-W., Ferrendelli, J. A., Covey, D. F., and Rothman, S. M. γ -Butyrolactone antagonism of the picrotoxin receptor: Comparison of a pure antagonist and a mixed antagonist/inverse agonist, 79
Hory, F., *see* Wall, S. J., 643
Huang, L. B. F., *see* Torphy, T. J., 376
Huang, P. and Plunkett, W. Action of 9- β -D-arabinofuranosyl-2-fluoroadenine on RNA metabolism, 449
Huwylar, J., B rgin, M., Zeuglin, T., and Gut, J. Transformation of 5-hydroperoxyeicosatetraenoic acid into dihydroxy- and cysteinyl-leukotrienes by rat hepatocytes: Effects of glutathione, 314
Hwang, S.-B., and Wang, S. Wheat germ agglutinin potentiates specific binding of platelet-activating factor to human platelet membranes and induces platelet-activating factor synthesis in intact platelets, 788
- I
- Iida, T., *see* Stojilkovi , S. S., 762
Ilett, K. F., *see* Reeves, P. T., 42
Im, W. B. and Blakeman, D. P. Correlation between γ -aminobutyric acid_A receptor ligand-induced changes in *t*-butylbicyclophephor[³⁵S]thionate binding and ³⁶Cl⁻ uptake in rat cerebrocortical membranes, 394
Imaoka, S., *see* Kanazawa, Y., 456
Insel, P. A., *see* Klijn, K., 407
Inukai, Y., *see* Kanazawa, Y., 456
Ito, M., *see* Baba, M., 805
Itzhak, Y., Mash, D., Zhang, S.-H., and Stein, I. Characterization of *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: Mutual effects of monoamine oxidase inhibitors and σ ligands on MPTP and σ binding sites, 385
Ivins, K. J., Luedtke, R. R., Artymyshyn, R. P., and Molinoff, P. B.

Regulation of dopamine D2 receptors in a novel cell line (SUP1), 531

Iwaniec, L. M., Kroll, J. J., Roethel, W. M., and Maybaum, J. Selective inhibition of sequence-specific protein-DNA interactions by incorporation of 6-thioguanine: Cleavage by restriction endonucleases, 299

J

- Jacobson, A. E., *see* Rothman, R. B., 222
Jacobson, K. A., *see* Nanoff, C., 130
Jamis-Dow, C. A., *see* Chu, E., 136
Jansen, R. W., Molema, G., Pauwels, R., Schols, D., De Clercq, E., and Meijer, D. K. F. Potent *in vitro* anti-human immunodeficiency virus-1 activity of modified human serum albumins, 818
Jarvis, M. F., Williams, M., Do, U. H., Sills, M. A. Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [³H]CGS 15943, to multiple affinity states of the adenosine A₁ receptor in the rat cortex, 49
Jensen, B. C., *see* Hoke, G. D., 90
Ji, H., Sandberg, K., and Catt, K. J. Novel angiotensin II antagonists distinguish amphibian from mammalian angiotensin II receptors expressed in *Xenopus laevis* oocyte, 120
Johnson, R. A., Arneson-Rotert, L. J., Hoffman, J. M., and Toews, M. L. Serum-induced sensitization of cyclic AMP accumulation in 1321N1 human astrocytoma cells, 399
Johnson, R. K., *see* Hoke, G. D., 90
Johnson, R. K., *see* McHale, M. M., 109
Jones, S. B., Halenda, S. P., and Bylund, D. B. α_2 -adrenergic receptor stimulation of phospholipase A₂ and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms, 239
Jordan, V. C., *see* Murphy, C. S., 421

K

- Kado, R. T., *see* Geoffroy, M., 587
Kallen, R. G., *see* White, M. M., 604
Kamataki, T., *see* Kanazawa, Y., 456
Kanazawa, Y., Kitada, M., Mori, T., Inukai, Y., Imaoka, S., Funae, Y., and Kamataki, T. Ascorbic acid deficiency decreases specific forms of cytochrome P-450 in liver microsomes of guinea pigs, 456
Kanterman, R. Y., Mahan, L. C., Briley, E. M., Monsma, F. J., Jr., Sibley, D. R., Axelrod, J., and Felder, C. C. Transfected D₂ dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells, 364
Karanian, J. W., *see* Montpied, P., 157
Kato, R., *see* Murayama, N., 811
Kauffman, F. C., Whittaker, M., Anundi, I., and Thurman, R. G. Futile cycling of a sulfate conjugate by isolated hepatocytes, 414
Kellar, K. J., *see* Pabreza, L. A., 9
Kelly, E. J., *see* Vertino, P. M., 487
Kemp, J. A., and Priestley, T. Effects of (*)-HA-966 and 7-chlorokynurenic acid on the kinetics of *N*-methyl-D-aspartate receptor agonist responses in rat cultured cortical neurons, 666
Khan, W., *see* Werner, M. H., 547
Kharbanda, S., *see* Rubin, E., 697
Kim, C.-H., *see* Rothman, R. B., 222
Kinnear, B. F., *see* Reeves, P. T., 42
Kinouchi, K., *see* Standifer, K. M., 290
Kitada, M., *see* Kanazawa, Y., 456
Klijn, K., Slivka, S. R., Bell, K., and Insel, P. A. Renal α_1 -adrenergic receptor subtypes: MDCK-D1 cells, but not rat cortical membranes possess a single population of receptors, 407
Klotz, K.-N., *see* Lohse, M. J., 517
Koeller, D. M., *see* Chu, E., 136
Koike, T., *see* Nakashima, S., 475
Kong, X.-B., Tong, W. P., and Chou, T.-C. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabi-

- nosylcytosine, 250
 Kopecka, H., *see* Lin, C. W., 346
 Kraner, J. C., *see* Raucy, J. L., 275
 Kroll, J. J., *see* Iwaniec, L. M., 299
 Krug, H. F. and Culig, H. Directed shift of fatty acids from phospholipids to triacylglycerols in HL-60 cells induced by nanomolar concentrations of triethyl lead chloride: Involvement of a pertussis toxin-sensitive pathway, 511
 Kufe, D., *see* Rubin, E., 697
 Kuhar, M. J., *see* Boja, J. W., 339
 Kuo, T., *see* Ganapathi, R., 1
 Kurtz, W. L., *see* Saussy, D. L., Jr., 72
- L**
- Laing, P., *see* Berger, S. P., 429
 Lambert, G., *see* Cornfield, L. J., 780
 Lambalez, B., *see* Geoffroy, M., 587
 Lasker, J. M., *see* Raucy, J. L., 275
 Lathrop, A. L., *see* Manoharan, T. H., 461
 Lawrence, T. S., *see* Dusenbury, C. E., 285
 Lefkowitz, R. J., *see* Campbell, P. T., 192
 Legendre, P. and Westbrook, G. L. Noncompetitive inhibition of γ -aminobutyric acid_A channels by Zn, 267
 Lévesque, D., and Di Paolo, T. Dopamine receptor reappearance after irreversible receptor blockade: Effect of chronic estradiol treatment of ovariectomized rats, 659
 Levy-Toledano, S., *see* Bernstrom, K., 114
 Lewandowski, G. A. and Cheng, Y.-C. Mechanism and mode of action of 5-iodo-2-pyrimidinone 2'-deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex virus-infected cells, 27
 Lewin, A. H., *see* Boja, J. W., 339
 Lieber, C. S., *see* Raucy, J. L., 275
 Liggett, S. B., *see* Bates, M. D., 55
 Lignon, M.-F., Bernad, N., and Martinez, J. Pharmacological characterization of type B cholecystokinin binding sites on the human JURKAT T lymphocyte cell line, 615
 Limbird, L. E., *see* Wilson, A. L., 481
 Lin, C. W., Shiosaki, K., Miller, T. R., Witte, D. G., Bianchi, B. R., Wolfram, C. A. W., Kopecka, H., Craig, R., Wagenaar, F., and Nadzan, A. M. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors, 346
 Lin, F. H., Clark, G., Birnbaum, L. S., Lucier, G. W., and Goldstein, J. A. Influence of the Ah locus on the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the hepatic epidermal growth factor receptor, 307
 Linton, J. C., *see* Gartland, K. P. R., 629
 Livi, G. P., *see* McHale, M. M., 109
 Loew, G. H., *see* Chew, C., 502
 Lohse, M. J., Klotz, K.-N., and Schwabe, U. Mechanism of A₂ adenosine receptor activation. I. Blockade of A₂ adenosine receptors by photo-affinity labeling, 517
 Lohse, M. J., *see* Gross, W., 524
 Lucas, R. C., *see* Stern, P. H., 557
 Lucier, G. W., *see* Lin, F. H., 307
 Luedtke, R. R., *see* Ivins, K. J., 531
 Luster, M. I., *see* Clark, G. C., 495
- M**
- MacDonell, K. L., *see* Hei, Y.-J., 233
 Maclouf, J., *see* Bernstrom, K., 114
 Magee, D. E., *see* Saussy, D. L., Jr., 72
 Mahan, L. C., *see* Kanterman, R. Y., 364
 Mahboubi, A., *see* Rothman, R. B., 222
 Mais, D. E., *see* Saussy, D. L., Jr., 72
 Maksay, G., Tegvey, Z., and Simonyi, M. Central benzodiazepine receptors: *In vitro* efficacies and potencies of 3-substituted 1,4-benzodiazepine stereoisomers, 725
 Malcolm, K., *see* Bernstrom, K., 114
 Manoharan, T. H., Welch, P. J., Gulick, A. M., Puchalski, R. B., Lathrop, A. L., and Fahl, W. E. Expression of tandem glutathione S-transferase recombinant genes in COS cells for analysis of efficiency of protein expression and associated drug resistance, 461
 Martenson, R. E., *see* Berger, S. P., 429
 Martin, B. M., *see* Montpied, P., 157
 Martin, B. M., *see* Wall, S. J., 643
 Martinez, J., *see* Lignon, M.-F., 615
 Mash, D., *see* Itzhak, Y., 385
 Mata, F., *see* Rius, C., 442
 Matsumoto, K. and Pappano, A. J. Carbachol activates a novel sodium current in isolated guinea pig ventricular myocytes via M₂ muscarinic receptors, 359
 Maybaum, J., *see* Dusenbury, C. E., 285
 Maybaum, J., *see* Iwaniec, L. M., 299
 McBain, J., *see* Safrany, S. T., 754
 McCabe, F. L., *see* Hoke, G. D., 90
 McCague, R., *see* Murphy, C. S., 421
 McGee, J., *see* Bernstrom, K., 114
 McHale, M. M., Cieslinski, L. B., Eng, W.-K., Johnson, R. K., Torphy, T. J., and Livi, G. P. Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast, 109
 McLarnon, J. G. and Wang, X.-P. Actions of cardiac drugs on a calcium-dependent potassium channel in hippocampal neurons, 540
 McNeill, J. H., *see* Hei, Y.-J., 233
 Meijer, D. K. F., *see* Jansen, R. W., 818
 Mellin, C., *see* Cornfield, L. J., 780
 Memo, M., Bovolin, P., Costa, E., and Grayson, D. R. Regulation of γ -aminobutyric acid_A receptor subunit expression by activation of N-methyl-D-aspartate-selective glutamate receptors, 599
 Merelli, F., *see* Stojilković, S. S., 762
 Mertelsmann, R., *see* Henschler, R., 171
 Meyer, U. A., *see* Grant, D. M., 184
 Meysmans, L., *see* Chatelain, P., 64
 Miller, K. W., *see* Wood, S. C., 332
 Miller, L. G., Galpern, W. R., Dunlap, K., Dinarello, C. A., and Turner, T. J. Interleukin-1 augments γ -aminobutyric acid_A receptor function in brain, 105
 Miller, L. J., *see* Molero, X., 150
 Miller, L. J., *see* Otterness, D. M., 34
 Miller, T. R., *see* Lin, C. W., 346
 Minchin, R. F., *see* Reeves, P. T., 42
 Mirabelli, C. K., *see* Hoke, G. D., 90
 Miyasaka, T., *see* Baba, M., 805
 Mucchetti, I., *see* Fabrazzo, M., 144
 Molema, G., *see* Jansen, R. W., 818
 Molero, X. and Miller, L. J. The gall bladder cholecystokinin receptor exists in two guanine nucleotide-binding protein-regulated affinity states, 150
 Molinoff, P. B., *see* Ivins, K. J., 531
 Monsma, F. J., Jr., *see* Kanterman, R. Y., 364
 Montpied, P., Morrow, A. L., Karanian, J. W., Ginns, E. I., Martin, B. M., and Paul, S. M. Prolonged ethanol inhalation decreases γ -aminobutyric acid_A receptor α subunit mRNAs in the rat cerebral cortex, 157
 Morgan, E. T., *see* Wright, K., 468
 Mori, S., *see* Baba, M., 805
 Mori, T., *see* Kanazawa, Y., 456
 Moroson, B. A., *see* Pizzorno, G., 85
 Morrow, A. L., *see* Montpied, P., 157
 Mount, H., Quirion, R., Chaudieu, I., and Boksa, P. Inhibitory and potentiating influences of glycine on N-methyl-D-aspartate-

- evoked dopamine release from cultured rat mesencephalic cells, 205
- Murayama, N., Shimada, M., Yamazoe, Y., and Kato, R. Difference in the susceptibility of two phenobarbital-inducible forms, P450IIB1 and P450IIB2, to thyroid hormone- and growth hormone-induced suppression in rat liver: Phenobarbital-inducible P450IIB2 suppression by thyroid hormone acting directly, but not through the pituitary system, 811
- Murphy, C. S., Parker, C. J., McCague, R., and Jordan, V. C. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: Importance of hydroxyl group and side chain positioning for biological activity, 421
- Murthy, L. R., *see* Standifer, K. M., 290
- N**
- Nadzan, A. M., *see* Lin, C. W., 346
- Nahorski, S. R., *see* Baird, J. G., 745
- Nahorski, S. R., *see* Safrany, S. T., 754
- Nakashima, S., Koike, T., and Nozawa, Y. Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A₂-mediated human platelet responses, 475
- Nanoff, C., Jacobson, K. A., and Stiles, G. L. The A₂ adenosine receptor: Guanine nucleotide modulation of agonist binding is enhanced by proteolysis, 130
- Nelson, D. L., *see* Cornfield, L. J., 780
- Nettesheim, P., *see* Duniec, Z. M., 164
- Nettleton, J., Castle, N. A., and Wang, G. K. Block of single batrachotoxin-activated Na⁺ channels by clofilium, 352
- Neve, K. A., Tester, B. A., Henningsen, R. A., Spanoyannis, A., and Neve, R. L. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase, 733
- Neve, K. A. Regulation of dopamine D2 receptors by sodium and pH, 570
- Neve, R. L., *see* Neve, K. A., 733
- Nicholson, J. K., *see* Gartland, K. P. R., 629
- Nitta, I., *see* Baba, M., 805
- Nozawa, Y., *see* Nakashima, S., 475
- O**
- O'Brian, C. A., *see* Dong, Z., 563
- O'Donnell, J. K., Sweet, R. W., and Stadel, J. M. Expression and characterization of the long and short splice variants of G_α in S49 cyc⁻ cells, 702
- O'Dowd, B. F., *see* Campbell, P. T., 192
- Olianas, M. C., *see* Onali, P., 436
- Onali, P. and Olianas, M. C. Naturally occurring opioid receptor agonists stimulate adenylate cyclase activity in rat olfactory bulb, 436
- Ottersen, D. M., Powers, S. P., Miller, L. J., and Weinshilboum, R. M. 3'-phosphoadenosine-5'-phosphosulfate: Photoaffinity ligand for sulfotransferase enzymes, 34
- P**
- Pabreza, L. A., Dhawan, S., and Kellar, K. J. [³H]Cytisine binding to nicotinic cholinergic receptors in brain, 9
- Pappano, A. J., *see* Matsumoto, K., 359
- Parker, C. J., *see* Murphy, C. S., 421
- Pasternak, G. W., *see* Standifer, K. M., 290
- Paul, S. M., *see* Berger, S. P., 429
- Paul, S. M., *see* Montpied, P., 157
- Pauwels, R., *see* Jansen, R. W., 818
- Pessah, I. N., and Zimanyi, I. Characterization of multiple [³H]ryanodine binding sites on the Ca²⁺ release channel of sarcoplasmic reticulum from skeletal and cardiac muscle: Evidence for a sequential mechanism in ryanodine action, 679
- Philip, A., *see* Boja, J. W., 339
- Pizzorno, G., Sokoloski, J. A., Cashmore, A. R., Moroson, B. A., Cross, A. D., and Beardsley, G. P. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines, 85
- Plunkett, W., *see* Huang, P., 449
- Poland, A., Glover, E., and Bradfield, C. A. Characterization of polyclonal antibodies to the A_h receptor prepared by immunization with a synthetic peptide hapten, 20
- Poland, A., *see* Bradfield, C. A., 13
- Porter, C. W., *see* Vertino, P. M., 487
- Potter, B. V. L., *see* Safrany, S. T., 754
- Potter, L. T., Ballesteros, L. A., Bichajian, L. H., Ferrendelli, C. A., Fisher, A., Hanchett, H. E., and Zhang, R. Evidence for paired M₂ muscarinic receptors, 211
- Powers, S. P., *see* Ottersen, D. M., 34
- Priestley, T., *see* Kemp, J. A., 666
- Proll, M. A., and Clark, R. B. Potent G_i-mediated inhibition of adenylyl cyclase by a phosphonate analog of monooleylphosphatidate, 740
- Prusoff, W. H., *see* August, E. M., 246
- Puchalski, R. B., *see* Manoharan, T. H., 461
- Puia, G., Vicini, S., Seeburg, P. H., and Costa, E. Influence of recombinant γ-aminobutyric acid-_A receptor subunit composition on the action of allosteric modulators of γ-aminobutyric acid-gated Cl⁻ currents, 691
- Q**
- Quik, M., El-Bizri, H., Audhya, T., and Goldstein, G. Thymopoietin, a potent antagonist at nicotinic receptors in C2 muscle cell cultures, 324
- Quirion, R., *see* Mount, H., 205
- R**
- Radić, Z., Reiner, E., and Taylor, P. Role of the peripheral anionic site on acetylcholinesterase: Inhibition by substrates and coumarin derivatives, 98
- Rahman, M. A., *see* Boja, J. W., 339
- Raucy, J. L., Lasker, J. M., Kraner, J. C., Salazar, D. E., Lieber, C. S., and Corcoran, G. B. Induction of cytochrome P450IIE1 in the obese overfed rat, 275
- Reeves, P. T., Kinnear, B. F., Minchin, R. F., and Ilett, K. F. Immunological evidence for N-acetyltransferase isozymes in the rabbit, 42
- Reid, A., *see* Rothman, R. B., 222
- Reiner, E., *see* Radić, Z., 98
- Rice, K. C., *see* Berger, S. P., 429
- Rice, K. C., *see* Rothman, R. B., 222
- Rius, C., Zorrilla, A. R., Cabañas, C., Mata, F., Bernabeu, C., and Aller, P. Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: Induction of vimentin gene expression, 442
- Roethel, W. M., *see* Iwaniec, L. M., 299
- Rogawski, M. A., *see* Hershkowitz, N., 592
- Rossier, J., *see* Geoffroy, M., 587
- Rothman, R. B., Reid, A., Mahboubi, A., Kim, C.-H., De Costa, B. R., Jacobson, A. E., and Rice, K. C. Labeling by [³H]1,3-Di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: Evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by σ ligands, 222
- Rothman, S. M., *see* Holland, K. D., 79
- Rubin, E., Kharbada, S., Gunji, H., and Kufe, D. Activation of the c-*jun* protooncogene in human myeloid leukemia cells treated with etoposide, 697
- Rush, G. F., *see* Hoke, G. D., 90
- S**
- Sabolovic, N., *see* Fournel-Gigleux, S., 177
- Safrany, S. T., Wojcikiewicz, R. J. H., Strupish, J., McBain, J., Cooke, A. M., Potter, B. V. L., and Nahorski, S. R. Synthetic phosphoro-

- thioate-containing analogues of inositol 1,4,5-trisphosphate mobilize intracellular Ca^{2+} stores and interact differentially with inositol 1,4,5-trisphosphate 5-phosphatase and 3-kinase, 754
- Salazar, D. E., *see* Raucy, J. L., 275
- Sandberg, K., *see* Ji, H., 120
- Saussey, D. L., Jr., Mais, D. E., Dubé, G. P., Magee, D. E., Brune, K. A., Kurtz, W. L., and Williams, C. M. Characterization of a thromboxane A_2 /prostaglandin H_2 receptor in guinea pig lung membranes using a radioiodinated thromboxane mimetic, 72
- Scammell, J. G., *see* Whalin, M. E., 711
- Schinazi, R. F., *see* Cretton, E. M., 258
- Schols, D., *see* Jansen, R. W., 818
- Schwabe, U., *see* Lohse, M. J., 517
- Schwartz, R. D., Heuschneider, G., Edgar, P. P., and Cohn, J. A. cAMP analogs inhibit γ -aminobutyric acid-gated chloride flux and activate protein kinase A in brain synaptoneurosome, 370
- Seeburg, P. H., *see* Puia, G., 691
- Seibert, K., *see* Wilson, A. L., 481
- Seidenfeld, J., *see* Stern, P. H., 557
- Sekiya, K., *see* Baba, M., 805
- Senogles, S. E., *see* Bates, M. D., 55
- Senzel, L., *see* Werner, M. H., 547
- Sheldon, R. S., Hill, R. J., Taouis, M., and Wilson, L. M. Aminoalkyl structural requirements for interaction of lidocaine with the class I antiarrhythmic drug receptor on rat cardiac myocytes, 609
- Shigeta, S., *see* Baba, M., 805
- Shimada, M., *see* Murayama, N., 811
- Shiosaki, K., *see* Lin, C. W., 346
- Sibley, D. R., *see* Barton, A. C., 650
- Sibley, D. R., *see* Kanterman, R. Y., 364
- Siest, G., *see* Fournel-Gigleux, S., 177
- Sills, M. A., *see* Jarvis, M. F., 49
- Simonyi, M., *see* Maksay, G., 725
- Slivka, S. R., *see* Klijn, K., 407
- Snowman, A. M., *see* Ferris, C. D., 199
- Snyder, S. H., *see* Ferris, C. D., 199
- Sokoloski, J. A., *see* Pizzorno, G., 85
- Sommadossi, J. P., *see* Cretton, E. M., 258
- Spanoyannis, A., *see* Neve, K. A., 733
- Stadel, J. M., *see* O'Donnell, J. K., 702
- Standifer, K. M., Murthy, L. R., Kinouchi, K., Steele, L., and Paster-nak, G. W. Affinity labeling of μ and κ receptors with naloxone benzoylhydrazone, 290
- Steele, L., *see* Standifer, K. M., 290
- Stein, I., *see* Itzhak, Y., 385
- Stern, P. H., Lucas, R. C., and Seidenfeld, J. α -Difluoromethylornithine inhibits bone resorption *in vitro* without decreasing β -glucuronidase release, 557
- Stiles, G. L., *see* Nanoff, C., 130
- Stojilković, S. S., Iida, T., Merelli, F., and Catt, K. J. Calcium signaling and secretory responses in endothelin-stimulated anterior pituitary cells, 762
- Strada, S. J., *see* Whalin, M. E., 711
- Strupish, J., *see* Safrany, S. T., 754
- Sung, C. M., *see* Hoke, G. D., 90
- Sutherland, L., *see* Fournel-Gigleux, S., 177
- Sweet, R. W., *see* O'Donnell, J. K., 702
- T**
- Takashima, H., *see* Baba, M., 805
- Tanaka, H., *see* Baba, M., 805
- Taouis, M., *see* Sheldon, R. S., 609
- Taylor, P., *see* Radić, Z., 98
- Teeter, L., *see* Ganapathi, R., 1
- Tegyey, Z., *see* Maksay, G., 725
- Tester, B. A., *see* Neve, K. A., 733
- Thompson, W. J., *see* Whalin, M. E., 711
- Thurkauf, A., *see* Berger, S. P., 429
- Thurman, R. G., *see* Kauffman, F. C., 414
- Toews, M. L., *see* Johnson, R. A., 399
- Tong, W. P., *see* Kong, X.-B., 250
- Torphy, T. J., *see* McHale, M. M., 109
- Torphy, T. J., Zhou, H.-L., Burman, M., and Huang, L. B. F. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis, 376
- Tsuji, J.-I., *see* Guthrie, T. S., 621
- Turner, T. J., *see* Miller, L. G., 105
- U**
- Ubasawa, M., *see* Baba, M., 805
- Ullrich, V., *see* Brüne, B., 671
- Umez, K., *see* Baba, M., 805
- V**
- Vallgård, J., *see* Cornfield, L. J., 780
- Vazquez-Padua, M., *see* Chen, C.-H., 625
- Vertino, P. M., Beerman, T. A., Kelly, E. J., Bergeron, R. J., and Porter, C. W. Selective cellular depletion of mitochondrial DNA by the polyamine analog $\text{N}^1, \text{N}^{12}$ -bis(ethyl)spermine and its relationship to polyamine structure and function, 487
- Vicini, S., *see* Puia, G., 691
- Villar, H. O., *see* Chew, C., 502
- W**
- Wagenaar, F., *see* Lin, C. W., 346
- Walker, R. T., *see* Baba, M., 805
- Wall, S. J., Yasuda, R. P., Hory, F., Flagg, S., Martin, B. M., Ginns, E. I., and Wolfe, B. B. Production of antisera selective for m1 muscarinic receptors using fusion proteins: Distribution of m1 receptors in rat brain, 643
- Wang, G. K., *see* Nettleton, J., 352
- Wang, S., *see* Hwang, S.-B., 788
- Wang, X.-P., *see* McLarnon, J. G., 540
- Ward, N. E., *see* Dong, Z., 563
- Weinshilboum, R. M., *see* Otterness, D. M., 34
- Welch, P. J., *see* Manoharan, T. H., 461
- Wells, J. N., *see* Guthrie, T. S., 621
- Werner, M. H., Senzel, L., Bielawska, A., Khan, W., and Hannun, Y. A. Diacylglycerol overcomes aspirin inhibition of platelets: Evidence for a necessary role for diacylglycerol accumulation in platelet activation, 547
- Westbrook, G. L., *see* Legendre, P., 267
- Whalin, M. E., Scammell, J. G., Strada, S. J., and Thompson, W. J. Phosphodiesterase II, cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells, 711
- White, M. M., Chen, L., Kallen, R. G., and Barchi, R. L. SkM2, A Na^+ channel cDNA clone from denervated skeletal muscle, encodes a tetrodotoxin-insensitive Na^+ channel, 604
- Whittaker, M., *see* Kauffman, F. C., 414
- Williams, C. M., *see* Saussey, D. L., Jr., 72
- Williams, M., *see* Jarvis, M. F., 49
- Wilson, A. L., Seibert, K., Brandon, S., Cragoe, E. J., Jr., and Limbird, L. E. Monovalent cation and amiloride analog modulation of adrenergic ligand binding to the unglycosylated α_{2B} -adrenergic receptor subtype, 481
- Wilson, L. M., *see* Sheldon, R. S., 609
- Witte, D. G., *see* Lin, C. W., 346
- Wojcikiewicz, R. J. H., *see* Safrany, S. T., 754
- Wolfe, B. B., *see* Wall, S. J., 643
- Wolfram, C. A. W., *see* Lin, C. W., 346
- Wood, S. C., Forman, S. A., and Miller, K. W. Short chain and long chain alkanols have different sites of action on nicotinic acetylcholine receptor channels from *torpedo*, 332
- Wright, K. and Morgan, E. T. Regulation of cytochrome P450IIC12

expression by interleukin-1 α , interleukin-6, and dexamethasone, 468

X

Xie, M.-Y., *see* Cretton, E. M., 258

Y

Yamazoe, Y., *see* Murayama, N., 811

Yasuda, R. P., *see* Wall, S. J., 643

Yeh, G. C., *see* Chu, E., 136

Yoon, K.-W., *see* Holland, K. D., 79

Z

Zeugin, T., *see* Huwyler, J., 314

Zhang, R., *see* Potter, L. T., 211

Zhang, S.-H., *see* Itzhak, Y., 385

Zhou, H.-L., *see* Torphy, T. J., 376

Zimanyi, I., *see* Pessah, I. N., 679

Zinn, S., *see* Chu, E., 136

Zorrilla, A. R., *see* Rius, C., 442

SUBJECT INDEX FOR VOLUME 39

A

- Acetylcholine, potent nicotinic receptor antagonist, thymopoietin, C2 muscle cell cultures, 324
- Acetylcholinesterase, peripheral anionic site, inhibition by substrates, coumarin derivatives, 98
- N-Acetyltransferase, isozymes, immunological evidence (rabbit), 42
- Acycloviridine, 6-substituted, selective inhibition, HIV-1, 805
- S-Adenosylhomocysteine hydrolase, potent inhibitor, mechanism of antiviral and cytotoxic action, 6'- β -fluoroaristeromycin, 718
- Adenylate cyclase
activity in olfactory bulb, naturally occurring opioid receptor agonists (rat), 436
mechanism of A₂ adenosine receptor activation
blockade by photoaffinity labeling, 517
collision-coupling model, 524
negative coupling, intrinsic activity of 8-hydroxy-2-(di-*n*-propylamino)tetralin, 5-HT_{1A}, 780
phospholipase A₂ and, α_2 -adrenergic receptor stimulation, CHO cells, 239
- Adenylyl cyclase
agonist-induced desensitization, D₂ dopamine receptors, 650
long and short splice variants of G_s, S49 cyc⁻ cells, 702
potent G_i-mediated inhibition, phosphate analog, monooleylphosphatidate, 740
regulation of dopamine D₂ receptor affinity, aspartate-80, 733
sensitization, D₂ dopamine receptors (mouse), 55
serum-induced sensitization, cyclic AMP accumulation, astrocytoma cells, 399
- Adrenoceptors
 α -1, renal subtypes, MDCK-D1 cells, 407
 α -2, phospholipase A₂ and adenylate cyclase, CHO cells, 239
 β -2, sequestration, down-regulation, 192
- Adriamycin, multidrug resistance, induction of thymidylate synthase, breast and colon cancer cell lines (human), 136
- Ah locus, influence on 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, hepatic epidermal growth factor receptor, 307
- Albumin, modified human serum, potent anti-HIV-1 activity, 818
- Alkanols, short chain and long chain, nicotinic acetylcholine receptor channels (*Torpedo*), 332
- Amiloride, regulation of dopamine D₂ receptors, sodium and pH, 570
- Amiloride analog, modulation of adrenergic ligand binding, unglycosylated α_{2B} -adrenergic receptor subtype, 481
- Amino acid, N-terminal sequence, Ah receptor (mouse), 13
- γ -Aminobutyric acid
channels, noncompetitive inhibition by zinc (rat), 267
-gated chloride flux, inhibition by cAMP analogs, brain synaptoneuroosomes (rat), 370
-gated Cl⁻ currents, action of allosteric modulators, GABA_A-receptor subunit composition, 691
- α -Amino-3-hydroxy-5-methylisoxazole-4-propionate, receptor, reduction of desensitization, 6-cyano-7-nitroquinoxaline-2,3-dione and 6,7-dinitroquinoxaline-2,3-dione (rat), 587
- Angiotensin II
antagonists, amphibian and mammalian receptors, *Xenopus laevis* oocytes, 120
DuP 753 effects, liver (rat), 579
- Antiarrhythmic drugs, lidocaine interaction, aminoalkyl structural requirements, cardiac myocytes (rat), 609
- Antisera, production using fusion proteins, M1 muscarinic receptors, brain (rat), 643
- 1- β -D-Arabinofuranosylcytosine, induction of *c-jun*, myeloid leukemia cell line, 171

- 9- β -D-Arabinofuranosyl-2-fluoroadenine, action on RNA metabolism, 449
- Arabinosylcytosine, resistance of HL-60 cells, induction of deoxycytidine kinase, 5-azacytidine, 250
- Arachidonic acid
release in CHO cells, transfected D₂ dopamine receptors, 364
renal α_1 -adrenergic receptor subtypes, MDCK-D1 cells, 407
- Artery, coronary, inhibition of phorbol-12,13-dibutyrate effect, protein kinase C (pig), 621
- Arylamine N-acetyltransferases, monomorphic and polymorphic, comparison of isozymes, two cloned genes, 184
- Ascorbic acid, deficiency, cytochrome P-450, liver microsomes (guinea pig), 456
- Aspartate-80, regulation of dopamine D₂ receptor affinity, inhibition of adenylyl cyclase, 733
- Aspirin, inhibition of platelets, effect of diacylglycerol, 547
- Astrocytoma cells, serum-induced sensitization, cyclic AMP accumulation, 399
- 5-Azacytidine, induction of deoxycytidine kinase, resistance to arabinosylcytosine, HL-60 cells, 250
- 3'-Azido-3'-deoxythymidine, catabolism in hepatocytes and liver microsomes (rat), 258
- 3-Azido[³H]GBR-12935, photoaffinity labeling, dopamine reuptake carrier protein (rat), 429

B

- Batrachotoxin
-activated Na⁺ channels, block by clofilium (rabbit), 352
aminoalkyl structural requirements, lidocaine interaction, cardiac myocytes (rat), 609
- B cells, tyrosine phosphorylation, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin stimulation (mouse), 495
- 1,4-Benzodiazepine, 3-substituted- stereoisomers, efficacies and potencies, central benzodiazepine receptors, 725
- Bile acid, stable expression of UDP-glucuronosyltransferase cDNAs, V79 cell cultures, 177
- Bis(diphenylphosphine)ethane, resistance of murine P388 leukemia, 90
- N*¹,*N*¹²-Bis(ethyl)spermine, cellular depletion of mitochondrial DNA, 487
- Bone, inhibition of resorption, α -difluoromethylornithine, β -glucuronidase release (mouse), 557
- Bone marrow, catabolism of 3'-azido-3'-deoxythymidine, hepatocytes, liver microsomes (rat), 258
- Brain
augmentation of GABA_A receptor function, interleukin 1 (mouse), 105
cerebrocortical membranes, *t*-butylbicyclophosphoro[³⁵S]thionate binding, GABA_A receptor ligand (rat), 394
cortical neurons, NMDA receptor agonist responses, HA-966 and 7-chlorokynurenic acid (rat), 666
cytosine binding, nicotinic cholinergic receptors (rat), 9
high affinity binding sites, 1,3-di(2-tolyl)guanidine (guinea pig), 222
membranes, σ receptors, opipramol (rat), 199
MPTP binding sites (mouse), 385
production of antisera using fusion proteins, M1 muscarinic receptors (rat), 643
stimulation of nerve growth factor biosynthesis, reserpine (rat), 144
synaptoneuroosomes, GABA-gated chloride flux, inhibition by cAMP analogs (rat), 370
- Breast neoplasms, induction of thymidylate synthase, multidrug resistance (human), 136

- Buthionine sulfoximine, inhibition of cell colony formation, selenite, glutathione involvement, 281
- t*-Butylbicyclophosphoro[³⁵S]thionate, binding and ³⁶Cl⁻ uptake, GABA_A receptor ligand, cerebrotical membranes (rat), 394
- γ-Butyrolactone, antagonism of picrotoxin receptor (rat), 79
- ### C
- Calcitonin gene-related peptide, receptor in cerebellum, multiple affinity forms (rat), 798
- Calcium
- dependent potassium channel, actions of cardiac drugs, hippocampal neurons (rat), 540
 - signaling and secretory responses, endothelin-stimulated anterior pituitary cells, 762
 - synthetic phosphorothioate-containing analogues, inositol 1,4,5-trisphosphate, 754
- Calcium channel
- high affinity binding sites in brain, 1,3-di(2-tolyl)guanidine (guinea pig), 222
 - sarcoplasmic reticulum from skeletal and cardiac muscle, multiple ryanodine binding sites, 679
 - slow, SR 33557, heart sarcolemmal membranes, 64
- Carbachol, activation of novel sodium current, M₂ muscarinic receptors, ventricular myocytes (guinea pig), 359
- Carcinogens, *N*-acetyltransferase isozymes, immunological evidence (rabbit), 42
- Catecholamines, renal α₁-adrenergic receptor subtypes, MDCK-D1 cells, 407
- Cation channels, *N*-methyl-D-aspartate-activated, block by tetrahydroaminoacridine, hippocampal neurons (rat), 592
- Cations, monovalent, allosteric regulation, α_{2B}-adrenergic receptor subtype, 481
- Cerebellar granule cells, regulation of GABA_A receptor subunit, activation, NMDA-selective glutamate receptors (rat), 599
- Cerebellum, calcitonin gene-related peptide receptor, multiple affinity forms (rat), 798
- Cerebral cortex
- ionotropic and metabotropic receptors, quisqualate-stimulated accumulation (rat), 745
 - prolonged ethanol inhalation, GABA_A receptor α subunit mRNAs (rat), 157
- CGS 15943, binding to multiple affinity states, adenosine A₁ receptor, cortex (rat), 49
- Chloride
- t*-butylbicyclophosphoro[³⁵S]thionate binding, GABA_A ligand, cerebrotical membranes (rat), 394
 - GABA-gated flux, inhibition by cAMP analogs, brain synaptoneuroosomes (rat), 370
- Chloride currents, GABA-gated, action of allosteric modulators, GABA_A receptor subunit composition, 691
- 7-Chlorokynurenic acid, HA-966 and, NMDA receptor agonist responses, cortical neurons (rat), 666
- CHO cells
- α₂-adrenergic receptor stimulation, phospholipase A₂, adenylate cyclase, 239
 - transfected D₂ dopamine receptors, arachidonic acid release, 364
- Cholecystokinin
- receptor affinity states, guanine nucleotide-binding protein, gall bladder, 150
 - tetrapeptide analogues, high potency and selectivity, cholecystokinin-A receptors, 346
 - type B binding sites, Jurkat T lymphocyte cell line (human), 615
- Cholesterol, futile cycling of sulfate conjugate, hepatocytes (rat), 414
- Clofilium, block of single batrachotoxin-activated Na⁺ channels (rabbit), 352
- Cocaine, isothiocyanate derivatives, inhibition of ligand binding, dopamine transporter (rat), 339
- Colon cancer
- chemosensitivity of cells, intrinsic drug resistance, protein kinase C activators (human), 563
 - induction of thymidylate synthase, multidrug resistance (human), 136
- Cortex, binding of CGS 15943, multiple affinity states (rat), 49
- Coumarin, derivatives, peripheral anionic site, acetylcholinesterase, 98
- 6-Cyano-7-nitroquinoxaline-2,3-dione, 6,7-dinitroquinoxaline-2,3-dione and, reduction of desensitization, α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor (rat), 587
- Cyclic AMP
- accumulation
 - activation, protein kinase C isozymes, 124
 - serum-induced sensitization, astrocytoma cells, 399 - dependent protein kinase, vas deferens contraction, cyclic AMP analogs (rat), 233
 - phosphodiesterase IV, reversal of growth arrest phenotypes, phosphodiesterase-deficient yeast, 109
 - regulation of metabolism by phosphodiesterase II, PC12 cells, 711
- Cyclic AMP analogs, inhibition of GABA-gated chloride flux, activation of protein kinase A, brain synaptoneuroosomes (rat), 370
- Cytisine, binding to nicotinic cholinergic receptors, brain (rat), 9
- Cytochrome P-450, ascorbic acid deficiency, liver microsomes (guinea pig), 456
- Cytochrome P450IIB1, P450IIB2 and, susceptibility differences, suppression in liver (rat), 811
- Cytochrome P450IIC12, regulation of expression, interleukin 1α, interleukin 6 and dexamethasone, 468
- Cytochrome P450IIE1, induction, obesity, overfeeding (rat), 275
- ### D
- Deoxycytidine kinase, induction by 5-azacytidine, resistance to arabinosylcytosine, HL-60 cells, 250
- 3'-Deoxythymidin-2'-ene, permeation of human lymphocyte H9 cells, nonfacilitated diffusion, 246
- Dexamethasone, regulation of cytochrome P450IIC12 expression, 468
- Diacylglycerol, overcomes aspirin inhibition of platelets, 547
- 5,10-Dideazatetrahydrofolic acid, intracellular metabolism, human leukemia cell lines, 85
- α-Difluoromethylornithine, inhibition of bone resorption, no decrease, β-glucuronidase release (mouse), 557
- 1,3-Di(2-tolyl)guanidine, high affinity binding sites in brain (guinea pig), 222
- DNA
- interactions with sequence-specific protein, inhibition by 6-thioguanine, 299
 - megabase fragments, 5-fluorodeoxyuridine, HT29 cells, 285
 - mitochondrial, cellular depletion, *N*¹,*N*¹²-bis(ethyl)spermine, 487
- DNA, complementary, stable expression of UDP-glucuronosyltransferase, V79 cell cultures, 177
- DNA, mitochondrial, anti-HIV nucleoside analogs, delayed toxicity, 625
- DNA topoisomerase II, inhibitors, vimentin gene expression, U-937 cell differentiation, 442
- Dopamine
- NMDA-evoked release, glycine, mesencephalic cells (rat), 205
 - reuptake carrier protein, photoaffinity labeling, 3-azido[³H]GBR-12935 (rat), 429
 - transporter, isothiocyanate derivatives, cocaine (rat), 339
- Doxorubicin, P-glycoprotein expression, trifluoperazine efficacy, multidrug-resistant cells (mouse), 1
- Drug resistance
- efficiency of protein expression, tandem glutathione *S*-transferase recombinant genes (monkey), 461
 - intrinsic, protein kinase C activators, chemosensitivity of colon cancer cells (human), 563
- DuP 753, angiotensin II effects, liver (rat), 579

E

- Effectors, mechanism of A₂ adenosine receptor activation, collision-coupling model, 524
- Ehrlich cells, nucleoside transporter, ligand binding, nitrobenzylthiosine binding site, 771
- Endothelin, -stimulated anterior pituitary cells, calcium signaling, secretory responses, 762
- Enkephalin
affinity labeling of *mu* and *kappa* receptors, naloxone benzoylhydrazide, 290
cyclic opioid peptides, flexibility, solution conformation, 502
- 14,15-*cis*-Episulfide-eicosatrienoic acid, inhibition of ionophore-induced platelet aggregation, 114
- Estradiol, dopamine receptor reappearance, irreversible receptor blockade (rat), 659
- Ethanol
prolonged inhalation, GABA_A receptor α subunit mRNAs, cerebral cortex (rat), 157
short chain and long chain alkanols, nicotinic acetylcholine receptor channels (*Torpedo*), 332
- Etoposide, activation of *c-jun*, myeloid leukemia cells (human), 697

F

- Fatty acids, shift from phospholipids to triacylglycerols, triethyl lead chloride, HL-60 cells, 511
- 6' β -Fluoroaristeromycin, mechanism of antiviral and cytotoxic action, 718
- 5-Fluorodeoxyuridine, induction of megabase DNA fragments, HT29 cells, 285
- 5-Fluorouracil, multidrug resistance, induction of thymidylate synthase, breast and colon cancer cell lines (human), 136
- Fusion proteins, production of antisera, M1 muscarinic receptors, brain (rat), 643

G

- Gall bladder, cholecystokinin receptor, guanine nucleotide-binding protein, affinity states, 150
- Gene, monomorphic and polymorphic arylamine *N*-acetyltransferases, comparison of isozymes, 184
- Genistein, inhibition, thromboxane A₂-mediated human platelet responses, 475
- β -Glucuronidase, release, inhibition of bone resorption, α -difluoromethylornithine (mouse), 557
- Glutamate, reduction of desensitization of AMPA receptor, 6-cyano-7-nitroquinoxaline-2,3-dione, 6,7-dinitroquinoxaline-2,3-dione, 587
- Glutathione
inhibition of cell colony formation, selenite, 281
transformation of 5-hydroperoxyeicosatetraenoic acid, dihydroxy- and cysteinyl-leukotrienes, hepatocytes (rat), 314
- Glutathione *S*-transferase, tandem recombinant genes in COS cells, protein expression efficiency, drug resistance (monkey), 461
- Glycine
inhibitory and potentiating influences, NMDA-evoked dopamine release, mesencephalic cells (rat), 205
NMDA receptor agonist responses, HA-966 and 7-chlorokynurenic acid, cortical neurons (rat), 666
- G proteins, long and short splice variants of G_{i1a}, S49 *cuc*⁻ cells, 702
- Growth hormone, -induced suppression in liver, differences in susceptibility, P450IIB1 and P450IIB2 (rat), 811
- Guanine
nucleotide-binding protein
affinity states, gall bladder cholecystokinin, 150
 β_2 -adrenergic receptor mutations, down-regulation, 192
nucleotide modulation, A₂ adenosine receptor, agonist binding (rabbit), 130

Guanylate cyclase, activation, inhibition of main platelet functions, 12-hydroperoxyeicosatetraenoic acid, 671

H

- HA-966, 7-chlorokynurenic acid and, NMDA receptor agonist responses, cortical neurons (rat), 666
- Haloxon, peripheral anionic site on acetylcholinesterase, inhibition of substrates, coumarin derivatives, 98
- Heart
actions of cardiac drugs, calcium-dependent potassium channel, hippocampal neurons (rat), 540
cardiac myocytes, aminoalkyl structural requirements, lidocaine interaction (rat), 609
sarcolemmal membranes, slow calcium channel binding sites, SR 33557, 64
- HeLa cells, inhibition of cell colony formation, selenite, glutathione involvement, 281
- Hepatocytes
catabolism of 3'-azido-3'-deoxythymidine (rat), 258
futile cycling of sulfate conjugate (rat), 414
transformation of 5-hydroperoxyeicosatetraenoic acid, dihydroxy- and cysteinyl-leukotrienes, glutathione (rat), 314
- Herpes simplex virus, -infected cells, mechanism, 5-iodo-2-pyrimidinone 2'-deoxyribonucleoside, 27
- Hippocampus
neurons
actions of cardiac drugs, calcium-dependent potassium channel (rat), 540
tetrahydroaminoacridine block, NMDA-activated cation channels (rat), 592
noncompetitive inhibition, GABA_A channels, zinc (rat), 267
- HL-60 cells, resistance to arabinofuranosylcytosine, induction of deoxycytidine kinase, 5-azacytidine, 250
- HT29 cells, induction of megabase DNA fragments, 5-fluorodeoxyuridine, 285
- Human immunodeficiency virus, anti-HIV nucleoside analogs, mitochondrial DNA, delayed toxicity, 625
- Human immunodeficiency virus-1
highly potent and selective inhibition, 6-substituted acyclouridine derivatives, 805
potent anti-HIV-1 activity, modified human serum albumins, 818
- 5-Hydroperoxyeicosatetraenoic acid, transformation into dihydroxy- and cysteinyl-leukotrienes, hepatocytes, glutathione (rat), 314
- 12-Hydroperoxyeicosatetraenoic acid, inhibition of main platelet functions, activation, soluble guanylate cyclase, 671
- 8-Hydroxy-2-(di-*n*-propylamino)tetralin, intrinsic activity of enantiomers, 5-HT_{1A} receptors, negative coupling to adenylate cyclase, 780

I

- Immunosuppression, tyrosine phosphorylation in B cells, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin stimulation (mouse), 495
- Inositol 1,4,5-trisphosphate, synthetic phosphorothioate-containing analogues, mobilization of Ca²⁺ stores, 754
- Inositol polyphosphate, quisqualate-stimulated accumulation, ionotropic and metabotropic receptors, cerebral cortex (rat), 745
- Interleukin 1, augmentation of GABA_A receptor function, brain (mouse), 105
- Interleukin 1 α , interleukin 6 and, regulation, cytochrome P450IIC12 expression, 468
- 5-Iodo-2-pyrimidinone 2'-deoxyribonucleoside, mechanism and mode of action, herpes simplex virus-infected cells, 27
- Ion channels, GABA_A channels, noncompetitive inhibition, zinc (rat), 267
- Ionophore, -induced platelet aggregation, inhibition, 14,15-*cis*-episulfide-eicosatrienoic acid, 114

Isothiocyanate derivatives, cocaine, inhibition of ligand binding, dopamine transporter (rat), 339

K

Kidney, α_1 -adrenergic receptor subtypes, MDCK-D1 cells, 407

L

Leukemia, human cell lines, intracellular metabolism, 5,10-dideazatetrahydrofolic acid, 85

Leukemia, myeloid

activation of *c-jun*, etoposide (human), 697

induction of *c-jun*, 1- β -D-arabinofuranosylcytosine, 171

Leukemia, P388, resistance to bis(diphenylphosphine)ethane, 90

Leukotrienes, dihydroxy- and cysteinyl-, 5-hydroperoxyeicosatetraenoic acid, hepatocytes (rat), 314

Lidocaine, interaction with class I antiarrhythmic drug receptor, aminoalkyl structural requirements, cardiac myocytes (rat), 609

Ligands

σ , 1,3-di(2-tolyl)guanidine, high affinity binding sites in brain (guinea pig), 222

binding to Ehrlich cell nucleoside transporter, nitrobenzylthioinosine binding site, 771

photoaffinity, 3'-phosphoadenosine-5'-phosphosulfate, sulfotransferase enzymes, 34

Lipids, batrachotoxin-activated Na^+ channels, block by clofilium (rabbit), 352

Liver

N-acetyltransferase isozymes, immunological evidence (rabbit), 42

DuP 753, angiotensin II effects (rat), 579

epidermal growth factor receptor, *Ah* locus, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 307

monomorphic and polymorphic arylamine *N*-acetyltransferases, comparison of isozymes, 184

susceptibility of P450IIB1 and P450IIB2, thyroid hormone- and growth hormone-induced suppression (rat), 811

Liver microsomes

ascorbic acid deficiency, decreased specific forms, cytochrome P-450 (guinea pig), 456

catabolism of 3'-azido-3'-deoxythymidine (rat), 258

Lung, membranes, thromboxane A_2 /prostaglandin H_2 (guinea pig), 72

Lymphocytes, 3'-deoxythymidin-2'-ene permeation, nonfacilitated diffusion, 246

Lymphoid cell lines, Jurkat T lymphocyte cell line, type B cholecystokinin binding sites (human), 615

M

MCF-7 cells, nonisomerizable derivatives of tamoxifen, structure-activity relationships, 421

Mesencephalic cells, inhibitory and potentiating influences of glycine, NMDA-evoked dopamine release (rat), 205

N-Methyl-D-aspartate

-activated cation channels, block by tetrahydroaminoacridine, hippocampal neurons (rat), 592

-evoked dopamine release, glycine, mesencephalic cells (rat), 205

-selective glutamate receptors, regulation, GABA_A receptor subunit (rat), 599

N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, binding sites in brain (mouse), 385

4-Methylumbelliferone sulfate, futile cycling of sulfate conjugate, hepatocytes (rat), 414

Mitochondria

cellular depletion of DNA, $\text{N}^1, \text{N}^{12}$ -bis(ethyl)spermine, 487

DNA, anti-HIV nucleoside analogs, toxicity, 625

resistance of murine P388 leukemia, bis(diphenylphosphine)ethane, 90

Monoamine oxidase, inhibitors, *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine binding sites, brain (mouse), 385

Monooleylphosphatidate, phosphonate analog, potent G_i -mediated inhibition, adenylyl cyclase, 740

Morphine, affinity labeling of *mu* and *kappa* receptors, naloxone benzoylhydrazone, 290

Multidrug resistance

induction of thymidylate synthase, breast and colon cancer (human), 136

P-glycoprotein expression, efficacy of trifluoperazine (mouse), 1

Muscle, skeletal

cardiac and, Ca^{2+} release channel, multiple ryanodine binding sites, 679

SkM2, tetrodotoxin-insensitive Na^+ channel (*Xenopus laevis*), 604

Muscle, smooth, coronary artery, inhibition of phorbol-12,13-dibutyrate effect, protein kinase C (pig), 621

Muscle cells, potent nicotinic receptor antagonist, thymopietin, 324

Myocytes

cardiac, aminoalkyl structural requirements, lidocaine interaction (rat), 609

ventricular, activation of novel sodium current, carbachol (guinea pig), 359

N

Naloxone benzoylhydrazone, affinity labeling, *mu* and *kappa* receptors, 290

Nerve growth factor, stimulation of biosynthesis, reserpine, brain (rat), 144

Neurons

cortical, NMDA receptor agonist responses, HA-966 and 7-chlorokynurenic acid (rat), 666

hippocampal

actions of cardiac drugs, calcium-dependent potassium channel (rat), 540

tetrahydroaminoacridine block, NMDA-activated cation channels (rat), 592

Nitrobenzylthiosine, binding site, ligand binding, Ehrlich cell nucleoside transporter, 771

Nuclear magnetic resonance spectroscopy, proton, pattern recognition methods, urine, 629

Nucleoside analogs, sequence-specific protein-DNA interactions, inhibition by 6-thioguanine, 299

Nucleotide phosphodiesterase, cyclic, isozymes, intact trachealis (dog), 376

O

Obesity, overfeeding, induction, cytochrome P450IIE1 (rat), 275

Olfactory bulb, adenylate cyclase activity, naturally occurring opioid receptor agonists (rat), 436

Oocytes, *Xenopus laevis*, amphibian and mammalian receptors, angiotensin II antagonists, 120

Opioid peptides, cyclic, flexibility and solution conformation, 502

Opipramol, labeling of novel binding site, σ receptors, brain membranes (rat), 199

Ovary, dopamine receptor reappearance, irreversible receptor blockade (rat), 659

P

Pancreas, cholecystokinin tetrapeptide analogues, high potency and selectivity, cholecystokinin tetrapeptide analogues, 346

Parkinson, -like symptoms, MPTP binding sites, brain (mouse), 385

PC12 cells, regulation of cyclic AMP metabolism, phosphodiesterase II, 711

Peptides, synthetic haptens, *Ah* receptors, polyclonal antibodies (rabbit), 20

Pertussis toxin

adenylate cyclase sensitization, responsiveness, D_2 dopamine receptors (mouse), 55

directed shift of fatty acids, phospholipids to triacylglycerols, triethyl

- lead chloride, 511
 serum-induced sensitization, cyclic AMP accumulation, astrocytoma cells, 399
 P-glycoprotein, efficacy of trifluoperazine, multidrug-resistant cells (mouse), 1
 pH, sodium and, regulation, dopamine D₂ receptors, 570
 Phenobarbital, -inducible forms P450IIB1 and P450IIB2, thyroid hormone and growth hormone, suppression in liver (rat), 811
 Phorbol-12,13-dibutyrate, inhibition of effect, synthetic pseudosubstrate peptide of protein kinase C, coronary artery smooth muscle (pig), 621
 3'-Phosphoadenosine-5'-phosphosulfate, photoaffinity ligand, sulfotransferase enzymes, 34
 Phosphodiesterase, -deficient yeast, human cAMP phosphodiesterase isozyme IV, growth arrest phenotypes, 109
 Phosphodiesterase II, regulation of cyclic AMP metabolism, PC12 cells, 711
 Phospholipase A₂, adenylate cyclase and, α_2 -adrenergic receptor stimulation, CHO cells, 239
 Phospholipids, directed shift of fatty acids to triacylglycerols, triethyl lead chloride, HL-60 cells, 511
 Phosphorothioate, -containing analogues, inositol 1,4,5-trisphosphate, mobilization of Ca²⁺ stores, 754
 Photoaffinity labeling
 3-azido[³H]GBR-12935, dopamine reuptake carrier protein (rat), 429
 mechanism of A₂ adenosine receptor activation, 517
 Pituitary
 anterior, endothelin stimulation, calcium signaling and secretory responses, 762
 thyroid hormone- and growth hormone-induced suppression, P450IIB1 and P450IIB2, liver (rat), 811
 Platelet-activating factor, specific binding to human platelet membranes, wheat germ agglutinin, 788
 Platelets
 aspirin inhibition, effect of diacylglycerol, 547
 inhibition of main functions, 12-hydroperoxyeicosatetraenoic acid, soluble guanylate cyclase, 671
 ionophore-induced aggregation, inhibition, 14,15-*cis*-episulfide-eicosatrienoic acid, 114
 thromboxane A₂-mediated responses, inhibition by genistein, 475
 Polyamines, N¹,N¹²-bis(ethyl)spermine, cellular depletion, mitochondrial DNA, 487
 Polyclonal antibodies
 N-acetyltransferase isozymes, immunological evidence (rabbit), 42
 synthetic peptide hapten, Ah receptors (rabbit), 20
 Potassium channel, calcium-dependent, actions of cardiac drugs, hippocampal neurons (rat), 540
 Prolactin
 dopamine receptor reappearance, irreversible receptor blockade (rat), 659
 -secreting cell line, regulation, dopamine D₂ receptors, 531
 Propidium, peripheral anionic site on acetylcholinesterase, inhibition of substrates, coumarin derivatives, 98
 Prostaglandin H₂, thromboxane A₂ receptors, lung membranes (guinea pig), 72
 Prostaglandin H synthase, stimulation of mRNA levels, phorbol ester, protein kinase C, 164
 Protein, efficiency of expression and drug resistance, tandem glutathione S-transferase recombinant genes (monkey), 461
 Protein kinase, cyclic AMP-dependent, vas deferens contraction, cyclic AMP analogs (rat), 233
 Protein kinase A, GABA-gated chloride flux, inhibition by cAMP analogs, brain synaptoneurosomes (rat), 370
 Protein kinase C
 activators, intrinsic drug resistance, chemosensitivity of colon cancer cells (human), 563
 aspirin inhibition of platelets, effect of diacylglycerol, 547
 isozymes, activation, cyclic AMP accumulation, 124
 serum-induced sensitization, cyclic AMP accumulation, astrocytoma cells, 399
 stimulation of prostaglandin H synthase mRNA, phorbol ester, 164
 synthetic pseudosubstrate peptide, inhibition of phorbol-12,13-dibutyrate effect, permeabilized coronary artery muscle (pig), 621
 Proteolysis, A₂ adenosine receptor, guanine nucleotide modulation, agonist binding (rabbit), 130
 Protooncogenes
 c-jun
 activation with etoposide, myeloid leukemia cells (human), 697
 1- β -D-arabinofuranosylcytosine, myeloid leukemia, 171
- ## Q
- Quinpirole, adenylyl cyclase sensitization, responsiveness, D₂ dopamine receptors (mouse), 55
 Quisqualate, -stimulated inositol polyphosphate accumulation, ionotropic and metabotropic receptors, cerebral cortex (rat), 745
- ## R
- Receptors
 σ , binding site labeling, opipramol (rat), 199
 adenosine A₁, CGS binding, multiple affinity states (rat), 49
 adenosine A₂
 guanine nucleotide modulation, agonist binding (rabbit), 130
 mechanism of activation, collision-coupling model, 524
 mechanism of activation, photoaffinity labeling, 517
 Ah
 N-terminal amino acid sequence (mouse), 13
 polyclonal antibodies, synthetic peptide hapten (rabbit), 20
 α -Amino-3-hydroxy-5-methylisoxazole-4-propionate, reduction of desensitization, 6-cyano-7-nitroquinoxaline-2,3-dione and 6,7-dinitroquinoxaline-2,3-dione (rat), 587
 angiotensin II, amphibian and mammalian, angiotensin II antagonists, 120
 benzodiazepine, efficacies and potencies, 3-substituted 1,4-benzodiazepine stereoisomers, 725
 cholecystokinin, affinity states, gall bladder, 150
 cholecystokinin-A, high potency and selectivity, cholecystokinin tetrapeptide analogues, 346
 dopamine, reappearance after irreversible receptor blockade, estradiol (rat), 659
 dopamine D₂
 agonist-induced desensitization, Y-79 retinoblastoma cells, 650
 arachidonic acid release, CHO cells, 364
 desensitization, adenylyl cyclase sensitization (mouse), 55
 regulation, novel cell line, 531
 regulation by sodium and pH, 570
 regulation with aspartate-80, inhibition of adenylyl cyclase, 733
 estrogen, nonisomerizable derivatives of tamoxifen, structure-activity relationships, 421
 GABA_A
 action of allosteric modulators, GABA-gated Cl⁻ currents, 691
 activation, NMDA-selective glutamate receptors (rat), 599
 augmentation by IL-1, brain (mouse), 105
 α subunit mRNAs, prolonged ethanol inhalation (rat), 157
 t-butylbicyclophosphorothionate [³⁵S] binding, cerebrocortical membranes (rat), 394
 5-HT_{1A}, intrinsic activity of 8-hydroxy-2-(di-*n*-propylamino)tetralin, negative coupling to adenylate cyclase, 780
 ionotropic and metabotropic, quisqualate-stimulated inositol polyphosphate accumulation, cerebral cortex (rat), 745
 N-methyl-D-aspartate, agonist responses, HA-966 and 7-chlorokynurenic acid (rat), 666
 muscarinic M1, antisera production using fusion proteins, brain (rat), 643

- muscarinic M2
- carbachol-activated sodium current, ventricular myocytes (guinea pig), 359
- evidence for pairs, 211
- nicotinic, antagonist thymopietin, C2 muscle cell cultures, 324
- nicotinic acetylcholine, channels, short chain and long chain alkanols (*Torpedo*), 332
- nicotinic cholinergic, cytosine binding, brain (rat), 9
- opioid, agonists, adenylate cyclase activity in olfactory bulb (rat), 436
- opioid *mu* and *kappa*, affinity labeling, naloxone benzoylhydrazone, 290
- picrotoxin, γ -butyrolactone antagonism (rat), 79
- sigma*, MPTP binding sites, brain (mouse), 385
- thromboxane A₂/prostaglandin H₂, lung membranes (guinea pig), 72
- unglycosylated α_{2B} -adrenergic, monovalent cation and amiloride analog modulation, 481
- Reserpine, stimulation of nerve growth factor biosynthesis, brain (rat), 144
- Restriction endonucleases, sequence-specific protein-DNA interactions, inhibition by 6-thioguanine, 299
- Retinoblastoma cells, agonist-induced desensitization, D₂ dopamine receptors, 650
- RNA
 - mechanism of antiviral and cytotoxic action, 6'- β -fluoroaristeromycin, 718
 - metabolism, action of 9- β -D-arabinofuranosyl-2-fluoroadenine, 449
- RNA, messenger
 - GABA_A receptor α subunit, prolonged ethanol inhalation, cerebral cortex (rat), 157
 - prostaglandin H synthase, phorbol ester, protein kinase C, 164
- Ryanodine, multiple binding sites, Ca²⁺ release channel, sarcoplasmic reticulum, 679

S

- Sarcolemmal membranes, heart, slow calcium channel binding sites, SR 33557, 64
- S49 cyc⁻ cells, long and short splice variants of G_i, 702
- Selenite, inhibition of cell colony formation, glutathione, 281
- Serum, -induced sensitization, cyclic AMP accumulation, astrocytoma cells, 399
- Sodium, pH and, regulation, dopamine D₂ receptors, 570
- Sodium channel
 - aminoalkyl structural requirements, lidocaine interaction, cardiac myocytes (rat), 609
 - batrachotoxin-activated, block by clofilium (rabbit), 352
 - tetrodotoxin-insensitive, SkM2, denervated skeletal muscle (*Xenopus laevis*), 604
- Sodium current, activation by carbachol, M₂ muscarinic receptors, ventricular myocytes (guinea pig), 359
- SR 33557, slow calcium channel binding sites, heart sarcolemmal membranes, 64
- Steroids, stimulation of nerve growth factor biosynthesis, reserpine, brain (rat), 144
- Sulfate conjugate, futile cycling by hepatocytes (rat), 414
- Sulfotransferase
 - enzymes, 3'-phosphoadenosine-5'-phosphosulfate, 34
 - futile cycling of sulfate conjugate, hepatocytes (rat), 414
- Synaptoneurosome, brain, GABA-gated chloride flux, inhibition by cAMP analogs (rat), 370

T

- Tamoxifen, nonisomerizable derivatives, structure-activity relationships, 421

- T cells, Jurkat, type B cholecystokinin binding sites (human), 615
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
 - influence of *Ah* locus, hepatic epidermal growth factor receptor, 307
 - stimulation of tyrosine phosphorylation, immunosuppression, B cells (mouse), 495
- 12-*O*-Tetradecanoylphorbol-13-acetate, stimulation of prostaglandin H synthase mRNA, phorbol ester, protein kinase C, 164
- Tetrahydroaminoacridine, block, *N*-methyl-D-aspartate-activated cation channels, hippocampal neurons (rat), 592
- Tetrodotoxin, -insensitive Na⁺ channel, SkM2, denervated skeletal muscle (*Xenopus laevis*), 604
- 6-Thioguanine, inhibition, sequence-specific protein-DNA interactions, 299
- Thrombin, ionophore-induced platelet aggregation, 14,15-*cis*-epiulfide-eicosatrienoic acid, 114
- Thromboxane A₂
 - mediated human platelet responses, inhibition by genistein, 475
- prostaglandin H₂ receptor, lung membranes (guinea pig), 72
- Thymidine analogs, 3'-deoxythymidin-2'-ene permeation, nonfacilitated diffusion, H9 cells, 246
- Thymidylate synthase, induction, multidrug resistance, breast and colon cancer (human), 136
- Thymopietin, antagonist at nicotinic receptors, C2 muscle cell cultures, 324
- Thyroid hormone, -induced suppression in liver, differences in susceptibility, P450IIB1 and P450IIB2 (rat), 811
- Trachealis, role of cyclic nucleotide phosphodiesterase isozymes (dog), 376
- Triacylglycerols, directed shift of fatty acids from phospholipids, triethyl lead chloride, HL-60 cells, 511
- Trifluoperazine, efficacy, P-glycoprotein expression, multidrug-resistant cells (mouse), 1
- Tyrosine, phosphorylation in B cells, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin stimulation (mouse), 495

U

- U-937 cells, differentiation, DNA topoisomerase II inhibitors, vimentin gene expression, 442
- UDP-glucuronosyltransferase, stable expression of cDNAs, V79 cell cultures, 177
- Urine, application of pattern recognition methods, toxicological data, proton nuclear magnetic resonance spectroscopy, 629

V

- Vas deferens, inhibition of contraction by cAMP analogs, cAMP-dependent protein kinase (rat), 233
- V79 cells, stable expression of UDP-glucuronosyltransferase cDNAs, 177
- Vimentin, gene expression, DNA topoisomerase II inhibitors, U-937 cell differentiation, 442
- Vincristine, P-glycoprotein expression, trifluoperazine efficacy, multidrug-resistant cells (mouse), 1

W

- Wheat germ agglutinin, specific binding of platelet-activating factor, human platelet membranes, 788

X

- Xenopus laevis*, oocytes, amphibian and mammalian receptors, angiotensin II antagonists, 120

Z

- Zinc, noncompetitive inhibition, GABA_A channels (rat), 267

**Copyright © 1991 by the American Society for
Pharmacology and Experimental Therapeutics**

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. T. Kendall Harden, Editor, *Molecular Pharmacology*, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7368, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made. Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. If the submitted manuscript utilizes or makes bibliographic reference to articles in press, copies should be included with the manuscript. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baucke, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brien. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used ($\times$, $\circ$, $\bullet$, $\square$, $\blacksquare$, $\triangle$, $\blacktriangle$, $\odot$). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
1985 William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. T. Kendall Harden, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7368.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$90.00; institutional, \$195.00, single copy, \$17.00. FOREIGN: personal, \$120.00; institutional, \$225.00; single copy, \$20.00. (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions and renewals are entered to begin with the January or July issue.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD. 21202-3993 U. S. A.